https://medicalxpress.com/mens-health-news/ en-us Latest health news and information about Men's Health The prospective, multicenter, randomized phase 2 ZZ-FIRST clinical trial, led by the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Group, evaluated the androgen receptor pathway inhibitor (ARPI) enzalutamide plus the poly(ADP-ribose) polymerase inhibitor (PARPi) talazoparib versus enzalutamide alone in patients with high-tumor-burden metastatic prostate cancer who had not previously received hormone therapy. https://medicalxpress.com/news/2026-11-prostate-cancer-drug-combination-toxicity.html Tue, 10 Nov 2026 17:20:08 EST news713545981 A new study led by researchers at Oxford Population Health shows that higher levels of proteins involved in activating and coordinating the immune system were associated with a lower risk of developing prostate cancer. The findings suggest that the body's ability to recognize and respond to abnormal cells may play an important role in the early development of prostate cancer and could point to new approaches for preventing the disease. https://medicalxpress.com/news/2026-11-immune-proteins-clues-prostate-cancer.html Tue, 10 Nov 2026 05:00:01 EST news713449204 A rapidly growing online trend known as "looksmaxxing" may expose some boys and young men to significant physical and mental health risks, according to a new commentary published in the Journal of Adolescent Health. https://medicalxpress.com/news/2026-11-looksmaxxing-starvation-steroids-deliberate.html Mon, 09 Nov 2026 15:20:04 EST news713453403 University of California, Riverside, scientists have an explanation for why males and females respond differently to obesity. They report in PNAS Nexus that certain immune cell populations in fat tissue may protect against obesity-related inflammation while others may contribute to harmful metabolic changes. They found these immune cells, called eosinophils and traditionally associated with asthma and allergies, behave differently in males and females. https://medicalxpress.com/news/2026-11-obesity-affects-males-females-differently.html Mon, 09 Nov 2026 09:40:06 EST news713439001 A multi-institutional collaborative study led by researchers at the University of Chicago and the Fred Hutchinson Cancer Center has identified a previously unknown biological mechanism that controls cell identity and treatment resistance in advanced prostate cancer. https://medicalxpress.com/news/2026-11-biological-mechanism-therapy-resistance-advanced.html Sat, 07 Nov 2026 08:00:06 EST news712835726 Men are suffering poor health and dying younger while the companies that profit from their misery are turning over billions of dollars. https://medicalxpress.com/news/2026-11-manosphere-tobacco-gambling-premature-deaths.html Fri, 06 Nov 2026 09:40:01 EST news713180061 In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer. https://medicalxpress.com/news/2026-11-prostate-cancer-drug-clinical-trial.html Wed, 04 Nov 2026 10:40:20 EST news713008659 New research presented at TCT 2026 found similar short-term outcomes in women and men with intermediate-risk pulmonary embolism (PE) after aspiration thrombectomy, a catheter-based procedure to remove blood clots from arteries in the lungs, despite higher pretreatment risk among women. The results were simultaneously published in JSCAI. https://medicalxpress.com/news/2026-11-women-men-similar-short-term.html Tue, 03 Nov 2026 15:30:01 EST news712905501 Retired NFL players may have a high risk of undiagnosed, untreated coronary artery disease (CAD) that often occurs without symptoms, according to new, independent, preliminary research presented at the American Heart Association's Scientific Sessions 2026, held Nov. 6–9 in Chicago. https://medicalxpress.com/news/2026-10-nfl-players-notably-linemen-high.html Mon, 02 Nov 2026 05:00:35 EST news712558582 Researchers at Roswell Park Comprehensive Cancer Center have shown that hormone-blocking therapies commonly used to treat prostate cancers temporarily activate the body's immune response before those immune effects begin to fade over time. In a new publication in the Journal for Immunotherapy of Cancer, a team led by Kent Nastiuk, Ph.D., reports this discovery—and points the way to a treatment strategy for taking advantage of this window of opportunity. https://medicalxpress.com/news/2026-10-critical-window-boosting-immunotherapy-response.html Thu, 29 Oct 2026 08:20:25 EDT news712480025 Managing type 2 diabetes requires more than occasional visits to the doctor's office. Much of the work happens between appointments, making communication and support from others an important part of managing the condition. https://medicalxpress.com/news/2026-10-health-discrimination-silence-diabetes-conversations.html Wed, 28 Oct 2026 11:20:02 EDT news712403599 Higher animal protein intake was associated with lower blood testosterone levels, while higher plant protein intake was associated with higher levels, according to a new study from the University of Eastern Finland. The findings were published in the International Journal of Food Sciences and Nutrition. https://medicalxpress.com/news/2026-10-animal-proteins-associations-testosterone-men.html Wed, 28 Oct 2026 08:20:08 EDT news712391117 A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track. https://medicalxpress.com/news/2026-10-alpha-radiopharmaceutical-therapy-early-phase.html Tue, 27 Oct 2026 20:00:01 EDT news712314488 An updated clinical guideline from the American Society for Radiation Oncology (ASTRO) provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer. The guideline replaces ASTRO's 2018 recommendations and reflects a matured evidence base showing that shorter-course radiation therapy can maintain cancer control while reducing overall treatment burden for patients receiving definitive external beam radiation therapy (EBRT). The guideline was published in Practical Radiation Oncology. https://medicalxpress.com/news/2026-10-guideline-shorter-therapy-localized-prostate.html Tue, 27 Oct 2026 17:40:01 EDT news712327667 An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care. https://medicalxpress.com/news/2026-10-patients-apalutamide-hormone-therapy-surgery.html Mon, 26 Oct 2026 17:00:06 EDT news712248111 Adding darolutamide to standard treatment for aggressive prostate cancer reduced the risk of the disease spreading in an international phase 3 trial. https://medicalxpress.com/news/2026-10-treatment-approach-prostate-cancer.html Mon, 26 Oct 2026 15:00:10 EDT news712235464 Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026. https://medicalxpress.com/news/2026-10-adding-abiraterone-adt-docetaxel-survival.html Mon, 26 Oct 2026 09:40:01 EDT news712223305 An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis published in CANCER indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past. https://medicalxpress.com/news/2026-10-men-prostate-cancer-surveillance-treatment.html Mon, 26 Oct 2026 03:10:01 EDT news711893641 Prostate cancer is the most common cancer in men—in 2013, it affected more than 1 million men across the world. The cancer does not behave the same way in every patient, and doctors have long faced a difficult balancing act between identifying patients who will benefit from more intensive treatment and those who may do just as well without it. Treating someone more aggressively than necessary is associated with increased side effects and poorer quality of life. https://medicalxpress.com/news/2026-10-diagnostic-doctors-refine-prostate-cancer.html Fri, 23 Oct 2026 20:40:01 EDT news711972301 Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk profile of the therapy, while also shedding light on patient selection and use trends. This research was published in The Journal of Nuclear Medicine. https://medicalxpress.com/news/2026-10-real-world-results-benefit-antigen.html Fri, 23 Oct 2026 13:20:06 EDT news711977370 Male breast cancer is far less common than breast cancer in women, but it is usually discovered later: Men with breast cancer often receive the diagnosis after finding a breast lump on their own. Kathryn Ruddy, M.D., an oncologist at Mayo Clinic Comprehensive Cancer Center, explains key things to know about male breast cancer. https://medicalxpress.com/news/2026-10-male-breast-cancer-age-expert.html Thu, 22 Oct 2026 13:10:02 EDT news711887672 After years of rising sexually transmitted infection (STI) rates in Australia, new Burnet Institute–led research has found promising evidence that an existing antibiotic taken after sex may be helping to reduce syphilis and chlamydia diagnoses among gay and bisexual men. https://medicalxpress.com/news/2026-10-sti-antibiotic-gay-bisexual-men.html Wed, 21 Oct 2026 15:20:07 EDT news711806202 Proteins linked to the immune system, cell adhesion, blood vessel formation and known prostate cancer genes were associated with the future risk of developing prostate cancer, including aggressive disease, in a new study led by researchers at Oxford Population Health. https://medicalxpress.com/news/2026-10-blood-proteins-reveal-clues-prostate.html Wed, 21 Oct 2026 14:30:01 EDT news711792961 Why do some prostate cancers grow slowly for years, while others progress quickly to life-threatening metastatic disease? An international team of researchers co-led by the Ontario Institute for Cancer Research (OICR) and the University of Copenhagen has uncovered new clues in the genomes of prostate cancers. https://medicalxpress.com/news/2026-10-genomic-cancer-driver-reveals-clues.html Fri, 16 Oct 2026 16:20:09 EDT news711376921 Approximately 1 in 4 active-duty male U.S. Army personnel may have a morning testosterone measurement below a commonly used clinical threshold, according to new research from Pennington Biomedical Research Center published this week in JAMA. The findings provide estimates of low testosterone screening results across the active-duty Army population and offer insight into the potential implications of routine testosterone screening for military personnel. https://medicalxpress.com/news/2026-10-testosterone-screening-army-personnel.html Thu, 15 Oct 2026 13:20:06 EDT news711287534 The rapid expansion of private testosterone prescribing risks extending treatment beyond men with clearly defined need to people with nonspecific symptoms and borderline test results, for whom the balance of benefit and long-term risk is less certain, warn experts in The BMJ. https://medicalxpress.com/news/2026-10-private-testosterone-overtreatment-strain-nhs.html Wed, 14 Oct 2026 18:30:13 EDT news711194281 Adding the targeted radioactive drug 177Lu-PNT2002 to stereotactic body radiation therapy, or SBRT, may help keep recurrent prostate cancer under control longer than SBRT alone, according to new research led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center. https://medicalxpress.com/news/2026-10-radioactive-therapy-delay-recurrent-prostate.html Tue, 13 Oct 2026 11:40:31 EDT news711108050 Men in England diagnosed with incurable advanced prostate cancer are more likely to survive for at least three years than they were a decade ago, according to an analysis by the London School of Hygiene & Tropical Medicine (LSHTM) and partners. https://medicalxpress.com/news/2026-10-men-longer-incurable-prostate-cancer.html Thu, 08 Oct 2026 13:00:16 EDT news710675582 It took the better part of a century for maternal mortality to be recognized, forgotten and finally recognized again as an urgent public health crisis in the United States. In contrast, research shows fathers—particularly men in their 20s through early 40s—die disproportionately from preventable causes such as suicide, overdose, homicide and accidental injury. Yet paternal mortality is rarely examined in connection with the transition to parenthood. https://medicalxpress.com/news/2026-10-dads-dying-kids-born-tracking.html Thu, 08 Oct 2026 11:40:07 EDT news710670660 A new study revealed molecular features linked to more aggressive prostate cancer in a subset of patients who had been classified as low risk, highlighting biological differences that may not be apparent from clinical measures alone. The results could lead to new therapeutic strategies. https://medicalxpress.com/news/2026-10-prostate-tumors-reveal-molecular-linked.html Wed, 07 Oct 2026 16:40:06 EDT news710605686